About the Journal

SKIN is a peer-reviewed, open access, online only journal dedicated to providing free access globally to disseminate dermatological knowledge. Authors retain copyright in their articles, licensing publication of their content through use of Creative Commons CCBY license. The journal does not charge fees, and is supported by the National Society for Cutaneous Medicine. 


Read More

Current Issue

Vol. 9 No. 2 (2025): March 2025 Issue

Published: 2025-03-17

ISSUE HIGHLIGHTS

In-Depth Reviews

Olive Oil in Dermatology: Bridging Ancient Traditions with Modern Medicine

Zaryab Alam, Aasim Jaffri, Rahib Islam, M Zaid Shami, Hamza Malick, Aamir Hussain

Page 2152-2161

PDF KOL SUMMARY

Ocular Disease as a Comorbidity of Atopic Dermatitis

Kimberlee Tottori, David Tottori, James Del Rosso

Page 2162-2174

PDF

Expanding Therapeutic Applications of Tofacitinib in Immune-Mediated Skin Disorders: A Comprehensive Review

Nina Schur, Natasha Doshi, Lexi Garber, Marcia Ballantyne, Milaan Shah

Page 2175-2183

PDF

Challenges in Public Health: The Diagnosis and Treatment of Crusted Scabies

Alyssa Forsyth, Wenqin Du, Marshall Hall, Michael Carletti, Stephen Weis

Page 2184-2198

PDF

Original Research

Factors Associated with Advanced Presentations of Melanoma in the United States from 2004-2015: A National Cancer Database Analysis Cohort Study

Kennedy Sabharwal, Anna Lin, Katie Cook, Tim Malouff, Stephen Ko, Byron May, Leila Tolaymat, Pamela Patton, Robert Miller, Daniel Trifiletti, Mark Waddle

Page 2199-2211

PDF

Research Letters

Diagnostic Outcomes of Clinically Diagnosed Lichen Planus-Like Keratosis

Jordan Phillipps, James Ko, David Sheinbein

Page 2212-2215

PDF

Brief Articles

A Case of Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder

Dana Olsen, Michael Levitt, Shalini Vemula

Page 2216-2221

PDF

Unveiling Multiple Chronic Relapsing Plaques and Ulcerations in a Healthy Individual

Nattanicha Chaisrimaneepan, Thunyaporn Khoruamklang

Page 2222-2226

PDF

Trichoadenoma on the Dorsal Forearm

Rebecca Lapides, Hannah Porter, Anne Stowman, Nathan Bombardier, Mary Maloney

Page 2227-2231

PDF

Successful Treatment of Terbinafine-Induced Subacute Cutaneous Lupus Erythematosus With Upadacitinib

Chloe H Franzia, Grace Sclamberg, Alex M Glazer

Page 2232-2235

PDF

Cylindroma in a Young Woman with a Germline Checkpoint Kinase 2 Gene Mutation Case Report

Rebecca Rist, Kathryn Shahwan, Megan O'Connor

Page 2236-2240

PDF

A Verrucous Lesion on a Nose in HIV Seropositive Female: A Rare Case Report

Supriya Kachare, Vasudha Belgaumkar, Shekhar Pradhan

Page 2241-2245

PDF

A Granular Cell Tumor on the Finger of a 7-Year-Old Boy: A Case Report

Alberto Gómez Trigos, Luis Miguel Alfonso Fernández Gutiérrez, Eugenia Muñoz Ruiz, Edgardo Gomez Torres, Manuel Cervantes Guadarrama

Page 2246-2250

PDF

COVID-19 Vaccination as a Precipitating Factor in Cutaneous Lupus Erythematosus with Lupus Nephritis: A Clinical Case Report

Elisha M. Myers, Marla Rodriguez, Michelle Schneider, Sabrina Shearer

Page 2251-2255

PDF

Multiple Basal Cell Carcinomas Mimicking Segmental Neurofibromatosis: A Clinical Conundrum

Helen Chen, Andrew Ibrahim, Michelle Tarbox

Page 2256-2260

PDF

Short Communications

Dermoscopy of Gouty Tophus: Unveiling New Patterns

Rasha Moumna, Syrine Hamada, Laila Benzekri

Page 2261-2263

PDF

SKINmages: Clinical Images in Dermatology

Multiple Congenital Hemangiomas

Christopher Chino-Marin, Kristina M. Derrick, John McGovern, Sharon A. Glick

Page 2267-2269

PDF

Intraumbilical Mass with Cyclical Drainage

Alexis Coican

Page 2270-2271

PDF

Severe Bullous Hypersensitivity Reaction After Copperhead Snakebite and Antivenom Therapy

Isha Jhingan, BS, Charles F. Hojjat, BS, Francesca L. Veon, DO, Amanda S. Weissman, MD, Jeffrey D. McBride, MD, PhD, Lindsey K. Collins, MD

Page 2272-2274

PDF

Alopecia

Evaluating the Quality of Social Media Content on Platelet-Rich Plasma for Androgenetic Alopecia and Facial Aesthetics: A Cross-Sectional Study

Aysham Chaudry, DO, Angelica Marrero-Perez, MD, Robert J. Vanaria, Mark S. Nestor, MD, PhD

Page s559

PDF

Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents With Alopecia Areata

Hannah Humphries, Kent A. Hanson, Sergio Vañó-Galván, Andrew Messenger, Helen Tran, Lynne Napatalung, Keith L. Davis, Lizzi Esterberg, Ernest H. Law

Page s560

PDF

Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program

Hannah Humphries, Rodney Sinclair, Bianca Maria Piraccini, Laurent Misery, Claire Abasq, Julien Ringuet, Dalia Wajsbrot, Roger A. Edwards, Gianluca Bonfanti, Robert Wolk, Alexandre Lejeune, Brett King

Page s561

PDF

Longitudinal and Exploratory Genome-Wide Analysis in Alopecia AreaTA (LEGAATA): A Study of FinnGen Participants

Hannah Humphries, Victoria Basey, Lynn Petukhova, Regina C. Betz, Christos Tziotzios, Michael Simpson, Buket Basmanav, Laura Huilaja, Mary Pat Reeve, Alexandre Lejeune, Gulraj Matharu, Emmi Tikkanen, Simon Chen

Page s562

PDF

Hidradenitis Suppurativa

Bimekizumab Impact on Flare in Hidradenitis Suppurativa Over 2 Years: Data from BE HEARD EXT

Haley B. Naik, Steven Daveluy, Errol Prens, Ziad Reguiai, Pablo Fernandez-Peñas, Sayaka Yamaguchi, Bartosz Lukowski, Christina Crater, Leah Davis, Antonio Martorell-Calatayud

Page s568

PDF

Acne & Rosacea

Early Acne Improvements With Fixed-Combination Topical Therapy: Analysis of the First 4 Weeks of Treatment

Steven R. Feldman, Katie Lovell, Robin Yi, Emil Tanghetti, Leon Kircik, Linda Stein Gold, Ted Lain, Hilary Baldwin, Julie Harper, Eric Guenin

Page s554

PDF

Fixed‑Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Versus Adapalene 0.3%/Benzoyl Peroxide 2.5% Gels for Moderate‑to‑Severe Acne: Comparative Patient Journey

Lawrence Green, Leon H. Kircik, Julie C. Harper, Hilary Baldwin, Neal Bhatia, Zoe D. Draelos, Lawrence F. Eichenfield, Ted Lain, William P. Werschler, Karol Wroblewski, Eric Guenin

Page s555

PDF

Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Association of Efficacy With Cutaneous Safety/Tolerability Events

Steven R. Feldman, Linda Stein Gold, Emil Tanghetti, Leon H. Kircik, Eric Guenin

Page s556

PDF

Efficacy and Safety of Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Caucasian Participants With Moderate to Severe Acne

Glynis Ablon, Hilary Baldwin, Valerie Callender, Zoe D. Draelos, Michael Gold, Ted Lain, Leon H. Kircik, Emil Tanghetti, Karol Wroblewski, Eric Guenin

Page s557

PDF

Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Pooled Analysis by Age and Sex

Julie C. Harper, Heather C. Woolery-Lloyd, Hilary Baldwin, Valerie D. Callender, Michael Gold, Linda Stein Gold, Adelaide Hebert, Eric Guenin, Leon H. Kircik

Page s558

PDF

Miscellaneous

Inclusion of the Patient Voice in Developing Holistic Treatment Goals for Rare Skin Diseases

Emmylou Casanova, Yuzlina Binti Che Yaacob, Dale Reisner, Ana Cristina Hernandez Daly, Diamant Thaçi, Bruce Strober

Page s569

PDF

Emotional Anatomy: Botulinum Toxin and the Regulation of Mood

Robert J. Vanaria, Angelica C. Marrero-Perez, MD, Aysham Chaudry, DO, Z. Paul Lorenc, MD, Mark S. Nestor, MD, PhD

Page s570

PDF

Ratio of Nonmelanoma Skin Cancer Histologic Subtypes in a South Florida Dermatology Practice: High Incidence of Squamous Cell Carcinoma Subtypes

Angelica C. Marrero-Perez, MD, Robert J. Vanaria, Aysham Chaudry, DO, Brian Berman, MD, PhD, Mark S. Nestor, MD, PhD

Page s571

PDF

Safety Profile of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Integrated Data used in the US Prescribing Information

Linda Stein Gold, Gaia Gallo,, Maria Lucia Buziqui Piruzeli, Fangyi Zhao, Sarah Reifeis, Hany Elmaraghy, Mark Lebwohl

Page s572

PDF

Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years

Andrew Blauvelt, Vivian Laquer, Richard G. Langley, Chih-ho Hong, Christian Bjerregård Øland, Le Gjerum, Ann-Marie Tindberg, Kristian Reich

Page s573

PDF

Real-world Effectiveness of Tralokinumab in Adults with Atopic Dermatitis: Interim Data on Improvements in Patients with Head and Neck Atopic Dermatitis after up to 9 Months of Treatment in the TRACE Study

April Armstrong, Ahmed Ameen, Jerry Bagel, Teodora Festini, Ulla Ivens, Ida Vittrup, Andrew E Pink

Page s574

PDF

Real-world Effectiveness of Tralokinumab in Adults with Atopic Dermatitis: Interim Data on Improvements in Patients with Atopic Dermatitis with Hands and Feet Involvement after up to 9 Months of Treatment in the TRACE Study

Diamant Thaçi, Pierre André Becherel, Adrian Rodriguez, Teodora Festini, Ulla Ivens, Ida Vittrup, Mahreen Ameen

Page s575

PDF

Real-world Effectiveness of Tralokinumab in Adults with Atopic Dermatitis on the Genitals: Interim Data on Improvements in Physician-Assessed Disease Severity and Patient-Reported Outcomes in up to 3 Months of Treatment in the TRACE Study

Esther Serra-Baldrich, April W. Armstrong, Teodora Festini, Ulla Ivens, Ida Vittrup, Marni Wiseman

Page s576

PDF

Special Section on Skin Cancer

The i31-SLNB Identifies Patients with Cutaneous Melanoma Who Have Less than 5% Risk of SLN Positivity while the CP-GEP does not

J. Michael Guenther, Samuel Dierks, John Vetto

Page s563

PDF

Enabling Access to Prognostic Gene Expression Profile (GEP) Testing for Invasive Melanoma by Leveraging RNA-based Testing in the Diagnostic Workflow

Brooke Russell, Mark Sommer, Sherri Borman, Jeffrey Wilkinson, Kristen Oelschlager, Trisha Poteet, Brian Martin, Matthew Goldberg

Page s564

PDF

The Calculated Objective Response Rate (ORR) of 97% from Post-Hoc Analysis of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma (BCC)

Jonathan Kantor MD, Neal Bhatia MD, Lawrence Green MD, Jonathan Weiss MD, Kenneth Y. Tsai, MD, PhD, Cynthia Willson RN, BSN, Susan Cutler DMD, Jayson Rieger PhD, MBA, David K. Glover ME, PhD, Pamela Rumney RN, CCRC, Thomas F. Haws, Gary Goldenberg MD

Page s565

PDF

Nail Unit Disorders

Topical Antifungals for Onychomycosis: In Vitro Antifungal Activity, Ex Vivo Nail Penetration, and Clinical Efficacy

Ali Elabbasi, Ahmed Kadry, Warren Joseph, Boni Elewski, Shari Lipner, Eric Guenin, Mahmoud Ghannoum

Page s566

PDF

Efficacy and Safety of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Older Adults

Shari Lipner, Aditya Gupta, Warren S. Joseph, Boni Elewski, Eric Guenin, Tracey Vlahovic

Page s567

PDF

Posters from 2025 WCM and WCH Dermatology Conferences®: Psoriasis

Patient-Reported Outcomes with Roflumilast Foam 0.3% in Patients with Psoriasis of the Scalp and Body in the Phase 3 ARRECTOR Trial

Melinda Gooderham, Jerry Bagel, Seth Forman, Leon Kircik, Marni Wiseman, Benjamin Lockshin, Jennifer Soung, David Krupa, Saori Kato, David Berk, David Chu

Page s525

PDF

Bimekizumab Maintenance of Response at Every Visit Over 4 Years in Patients with Psoriasis Achieving Clear Skin at Week 16: Results from Four Phase 3 Trials

Mark Lebwohl, Richard B. Warren, Peter Foley, Georgios Kokolakis, Naiem T. Issa, Richard G. Langley, Balint Szilagyi, Bengt Hoepken, Heather Herr, Rhys Warham, April Armstrong

Page s526

PDF

Characterization of ORKA-001, a Novel Extended Half-life Monoclonal Antibody Targeting IL-23 for the Treatment of Psoriasis

Eugenia Levi, Byron Kwan, Mohammad Murshid Alam, Jacob Milligan, Soraia Oliveira, Christopher Finch, Joana Goncalves, Laura Sandler, Jason Oh, Hussam Shaheen

Page s527

PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: The Association Between Patient-Reported and Clinician-Reported Outcomes at Week 16 in a Phase 3b/4 Multicenter, Randomized, Double-blinded, Placebo-controlled Study (PSORIATYK SCALP)

Steven R. Feldman, Diamant Thaçi, Jerry Bagel, Eugene Balagula, Rachel Dyme, Yichen Zhong, Brandon Becker, Jennifer L. Beaumont, David M. Pariser, Mark Lebwohl

Page s528

PDF

Impact of GPP on Quality of Life and Psychological Well-being: Results from a Non-interventional Survey/Interview-based Study

Mark G. Lebwohl, Kilian Eyerich, Andrew E. Pink, Min Zheng, Iris Chen-Yin Lai, David Trigos, Anne M. Skalicky, Julia R. Correll, Ana C. Hernandez Daly, Patrick Hofmann, Hideki Fujita

Page s529

PDF

Real-world Experience with Spesolimab in Chinese Patients with GPP

Min Zheng, Furen Zhang, Yu-ling Shi, Xiaoming Liu, Aie Xu, Nichiren Pillai, Yuexiao Xu, Ada Chen, Rafael Sani Simoes, Xinghua Gao

Page s530

PDF

Long-Term Effectiveness of Guselkumab vs. Other Biologic Therapies Among Plaque Psoriasis Patients in the CorEvitas Psoriasis Registry

Bruce E. Strober, April W. Armstrong, Timothy Fitzgerald, Katelyn Rowland, Olivia Choi, Daphne Chan, Alvin H. Li, Adam P. Sima, Thomas Eckmann, Sandra Main, Mark G. Lebwohl

Page s531

PDF

Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-year, Long-term Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials

April W. Armstrong, Richard B. Warren, Bruce Strober, Andrew Blauvelt, Yayoi Tada, Thierry Passeron, Diamant Thaçi, Carolin Daamen, Janice Li, Zoran Popmihajlov, John Vaile, Julie Scotto, Mark Lebwohl

Page s532

PDF

Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-Reported Outcomes in a Phase 3b/4, Multicenter, Randomized, Double-blinded, Placebo-Controlled Study (PSORIATYK SCALP)

Linda Stein Gold, Michael Sebastian, Eugene Balagula, Brandon Becker, Yichen Zhong, Rachel Dyme, Michael DeRosa, Scott Fretzin, Andreas Pinter, Christopher E. M. Griffiths

Page s533

PDF

Deucravacitinib in Plaque Psoriasis: Immune Response to and Safety of Pneumococcus and Tetanus Toxoid Vaccines in the POETYK LTE Trial

Joanna Narbutt, Shahram Jacobs, Kim A. Papp, Alessandra Alió, Yi Luo, Yanqiu Shao, Victoria Berger, Carolin Daamen, Kevin Winthrop

Page s534

PDF

Impact of Deucravacitinib on Psoriasis Severity and Overall Patient-reported Outcomes in a US Prospective Cohort Study

Alexis Ogdie, Sarah Lonowski, Laetitia N’Dri, Vadim Khaychuk, Rebecca Schumacher, Kaleb Michaud

Page s535

PDF

Impact of Deucravacitinib on Scalp Psoriasis in a Real-world Prospective Cohort Study in the United States

Alexis Ogdie, Sarah Lonowski, Laetitia N’Dri, Vadim Khaychuk, Rebecca Schumacher, Kaleb Michaud

Page s536

PDF

Efficacy of Deucravacitinib over time in Psoriasis by Baseline Total Body Surface Area: Post Hoc Analysis of the Randomized, Double-blind, Placebo-controlled Phase 3b/4 PSORIATYK SCALP Trial

Christopher E.M. Griffiths, Matthias Hoffmann, Andrew Blauvelt, Eugene Balagula, Andrew Napoli, Chun-Yen Cheng, Rachel Dyme, Virginia Hala, Andreas Pinter, Mark Lebwohl

Page s537

PDF

Deucravacitinib in Psoriasis Patients with a History of Malignancy: Follow-up after 4 Years of Deucravacitinib Treatment in the POETYK PSO Program

Mark Lebwohl, Neil J. Korman, Melinda Gooderham, Alice B. Gottlieb, Peter Foley, Kilian Eyerich, Marco Romanelli, Bruce Strober, Akimichi Morita, Linfeng Li, Carolin Daamen, John Vaile, Ramesh Badaka, Alessandra Alió, Lluís Puig

Page s538

PDF

Onset of Clinical Response with Deucravacitinib in Patients with Moderate to Severe Scalp Psoriasis: A Post Hoc Analysis of the Phase 3b/4 PSORIATYK SCALP Trial

Matthias Hoffmann, Andrew Blauvelt, Eugene Balagula, Andrew Napoli, Chun-Yen Cheng, Rachel Dyme, Virginia Hala, Stephen Tyring, Jerry Bagel, Mark Lebwohl

Page s539

PDF

Generalized Pustular Psoriasis (GPP) Control is Limited on Traditional Small-molecule Therapy as Measured by the GPP Physician Global Assessment (GPPGA) and Dermatology Life Quality Index (DLQI): Baseline Data from the EFFISAYIL® 2 Trial

Arash Mostaghimi, Joseph Merola, Alice Gottlieb, Douglas DiRuggiero, Jason Guercio, Ming Tang, Christian Thoma, Mark Lebwohl

Page s540

PDF

The Chronicity and Disease Burden of Generalized Pustular Psoriasis

Thomas Selby, Joe Tung, Maria Aleshin, Angad Chadha, Jacquelyn Dosal, Laura Rezac, Brooke Walterscheid, Ella Solomon, Lauren Stephens, Benjamin Workman

Page s541

PDF

Treatment Outcomes and Management of Generalized Pustular Psoriasis with Spesolimab

Joe Tung, Thomas Selby, Maria Aleshin, Angad Chadha, Jacquelyn Dosal, Laura Rezac, Brooke Walterscheid, Ella Solomon, Lauren Stephens, Benjamin Workman

Page s542

PDF

Atopic Dermatitis

Lebrikizumab Improved Skin Signs, Quality of Life, and Showed High Levels of Patient Satisfaction in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis and Skin of Color

Valerie Callender, April Armstrong, Chesahna Kindred, Peter Lio, Zach Dawson, Evangeline Pierce, Jinglin Zhong, Lauren George, Andrew Alexis

Page s549

PDF

Half-life-extended monoclonal antibody APG777 for atopic dermatitis: Design of the phase 2 APEX study

Emma Guttman-Yassky, Andrew Blauvelt, Melinda Gooderham, Kenji Kabashima, Marilia Oliveira, Li Xie, Angela Wilson, Carl Dambkowski, Kristine Nograles, Jonathan Silverberg

Page s550

PDF

Preclinical Potency, Affinity, and Pharmacokinetics of APG990, a Half-Life Extended Antibody Against OX40L

Grant Wickman, Byong Ha Kang, Jessica Meinke, Steve Raso, Jason Oh, Hussam Shaheen, Lukas Dillinger

Page s551

PDF

Patient Experience and Preferences for Treatments in Atopic Dermatitis: Results from a US Patient Survey

Ann Quick, Lenka Hurton, Joshua Burshtein, Aaron Farberg, Matthew Goldberg, Olga Zolochevska, Peter Lio

Page s552

PDF

Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Robert Bissonnette, Linda Stein Gold, Leon Kircik, Eric Simpson, Lawrence F. Eichenfield, John Browning, Adelaide A. Hebert, Andrew F. Alexis, Weily Soong, Stephen C. Piscitelli, Anna M. Tallman, David S. Rubenstein, Philip M. Brown, Jonathan I. Silverberg

Page s553

PDF

Hyperpigmentation

Thiamidol (isobutylamido thiazolyl resorcinol): A Highly Specific Human Tyrosinase Inhibitor for the Treatment of Hyperpigmentation

Tobias Mann, Wolfram Gerwat, Jan Batzer, Kerstin Eggers, Cathrin Scherner, Horst Wenck, Franz Stab, Vincent Hearing, Klaus-Heinrich Rohm, Ludger Kolbe

Page s543

PDF

Clinical Efficacy of the Human Tyrosinase Inhibitor Thiamidol (isobutylamido thiazolyl resorcinol) in Melasma

Dennis Roggenkamp, Adel Sammain, Manuela Furstenau, Martina Kausch, Thierry Passeron, Ludger Kolbe

Page s544

PDF

Clinical Evaluation of the Human Tyrosinase Inhibitor Thiamidol (isobutylamido thiazolyl resorcinol) in Prevention of UVB-induced Hyperpigmentation

Vasanop Vachiramon, Chaninan Kositkuljorn, Kanchana Leerunyakul, Kumutnart Chanprapaph

Page s545

PDF

Effective Reduction of Acne-induced Post-inflammatory Hyperpigmentation with the Human Tyrosinase Inhibitor Thiamidol (isobutylamido thiazolyl resorcinol)

Dennis Roggenkamp, Ncoza Dlova, Tobias Mann, Jan Batzer, Julia Riedel, Martina Kausch, Ivica Zoric, Ludger Kolbe

Page s546

PDF

Combined Thiamidol and Low-fluence Q-switched Nd:YAG Laser for the Treatment of Facial Hyperpigmentation

Vasanop Vachiramon, Kanchana Leerunyakul, Chaninan Kositkuljorn, Pamela Chayavichitsilp

Page s547

PDF

Thiamidol: A Breakthrough Innovation in Treatment of Hyperpigmentation

Seemal Desai, Andrew Alexis, Hilary Baldwin, Valerie Callender, Nada Elbuluk, Patricia Farris, Pearl Grimes, Susan Taylor, Cheri Frey

Page s548

PDF
View All Issues